Scientists at the University of Pennsylvania destroyed tumors in three patients with chronic lymphocytic leukemia less than a month after administering the patients' T-cells that were genetically engineered to stimulate the immune system to hone in on the CD19 protein, which is found on blood cancer cells. Two patients achieved complete response to the treatment, while the third exhibited partial response. The therapy needs to be tested in more patients to validate the findings, the study's principal investigator said.

Related Summaries